Don't miss SGLT Tools - PowerPoint slide library for SGLT2 inhibitors

UKidney Nephrology News and Insights

No benefit of Aliskiren added on to ACE or ARB: a disappointing development

No benefit of Aliskiren added on to ACE or ARB: a disappointing development

Plasma Renin ActivityIn a stunning development, Novartis said Tuesday that it will terminate the late-stage ALTITUDE study investigating Rasilez (aliskiren) in patients with type 2 diabetes and renal impairment on the recommendation of an independent data monitoring committee. The company indicated that the committee concluded that "patients were unlikely to benefit" from the addition of Rasilez to standard anti-hypertensives and also identified higher adverse events in this group (source: FirstWord).

On a personal and professional note, these results come as a great disappointment to me. Not only does it suggest no further protection for our patients prescribed this strategy in an effort to reduce the burden of cardiorenal disease, but I was a great believer in the hypothesis and taught about it extensively throughout my career.

Cracks began to appear in the theory of aggressive renin-angiotensin inhibition with the ONTARGET, ACCOMPLISH, ASCEND and ROADMAP studies, where patients experienced no outcome benefit despite aggressive renin-angiotension and successful lowering of urinary albumin excretion. The ALTITUDE study will call in to question, not only the role of renin inhibition, but  the rationale for albuminuria reduction as well when attempted to reduce cardiovascular end-points.

As a cautionary note, we must await the publication of this study to fully understand the findings. Furthermore, Aliskiren has been shown to be a very safe antihypertensive following over 200,00 patient-years of data. But the combination of multiple (even) safe drugs in this class, like we saw in ONTARGET with ACEi and ARBs, is not a promising strategy any longer.

Finally, a tantalizing issue lingers in the story of renin inhibition; it is conceivable that direct renin inhibition is the best way to block this system, better than ACEi and ARBs, since the latter 2 cause reflexive increase in plasma renin activity whereas aliskiren does not. However, because aliskiren was introduced so late and no head-to-head or non-inferiorty studies were ever done against ACEi or ARBs, we will likely never know.

Treating microalbuminuria to reduce cardiovascular...
Generic drugs: a dangerous public misunderstanding...

Related Posts

 

Comments (10)

This comment was minimized by the moderator on the site

Very disappointing finding

This comment was minimized by the moderator on the site

Very disappointing finding

This comment was minimized by the moderator on the site

Thank you for posting this here. Very interesting result and I will look forward to seeing the published study. I find Aliskierin a very useful anti-hyper drug but it's a shame aggressive RAS blockade hasn't panned out as an effective strategy...

Thank you for posting this here. Very interesting result and I will look forward to seeing the published study. I find Aliskierin a very useful anti-hyper drug but it's a shame aggressive RAS blockade hasn't panned out as an effective strategy for managing DM2 pts with CKD.

This post was a well written commentary on the state of this research. I appreciate the refresher on the evidence on aggressive RAS blockade as well.

Read More
This comment was minimized by the moderator on the site

Thank you for posting this here. Very interesting result and I will look forward to seeing the published study. I find Aliskierin a very useful anti-hyper drug but it's a shame aggressive RAS blockade hasn't panned out as an effective strategy...

Thank you for posting this here. Very interesting result and I will look forward to seeing the published study. I find Aliskierin a very useful anti-hyper drug but it's a shame aggressive RAS blockade hasn't panned out as an effective strategy for managing DM2 pts with CKD.

This post was a well written commentary on the state of this research. I appreciate the refresher on the evidence on aggressive RAS blockade as well.

Read More
This comment was minimized by the moderator on the site

It seems the RAAS is very important physiologically, and that's why whenever we try to block this system, there is a way around, to keep producing angiotensin II. DRI are no exception as there are still alternate pathways. Personally, I was not a...

It seems the RAAS is very important physiologically, and that's why whenever we try to block this system, there is a way around, to keep producing angiotensin II. DRI are no exception as there are still alternate pathways. Personally, I was not a believer of DRI.

Read More
This comment was minimized by the moderator on the site

It seems the RAAS is very important physiologically, and that's why whenever we try to block this system, there is a way around, to keep producing angiotensin II. DRI are no exception as there are still alternate pathways. Personally, I was not a...

It seems the RAAS is very important physiologically, and that's why whenever we try to block this system, there is a way around, to keep producing angiotensin II. DRI are no exception as there are still alternate pathways. Personally, I was not a believer of DRI.

Read More
This comment was minimized by the moderator on the site

what Aliskiren ???????????????????

This comment was minimized by the moderator on the site

what Aliskiren ???????????????????

This comment was minimized by the moderator on the site

After all the money involved...
I really think we should be more cautious with new drugs. Here in Brazil almost every cardiologist is prescribing aliskiren combined with ARB for diabetic patients who can pay for it. We have seen an absurd amount...

After all the money involved...
I really think we should be more cautious with new drugs. Here in Brazil almost every cardiologist is prescribing aliskiren combined with ARB for diabetic patients who can pay for it. We have seen an absurd amount of propaganda here and Novartis is/was financing lots of congresses, journals, parties, travels, etc

Read More
This comment was minimized by the moderator on the site

After all the money involved...
I really think we should be more cautious with new drugs. Here in Brazil almost every cardiologist is prescribing aliskiren combined with ARB for diabetic patients who can pay for it. We have seen an absurd amount...

After all the money involved...
I really think we should be more cautious with new drugs. Here in Brazil almost every cardiologist is prescribing aliskiren combined with ARB for diabetic patients who can pay for it. We have seen an absurd amount of propaganda here and Novartis is/was financing lots of congresses, journals, parties, travels, etc

Read More
There are no comments posted here yet

Leave your comments

  1. Posting comment as a guest. Sign up or login to your account.
Attachments (0 / 3)
Share Your Location
ukidneyisup